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Abstract
Peripheral neuropathy is one of the major side-effects of the anticancer drug, cisplatin. Although
previous work suggests that this neuropathy correlates with formation of DNA adducts in sensory
neurons, growing evidence suggests that cisplatin also increases the generation of reactive oxygen
species (ROS), which could cause DNA damage. Apurinic/apyrimidinic endonuclease/redox factor-1
(Ape1/Ref-1) is a multifunctional protein involved in DNA base excision repair (BER) of oxidative
DNA damage and in redox regulation of a number of transcription factors. Therefore, we asked
whether altering Ape1 functions would influence cisplatin induced neurotoxicity. Sensory neurons
in culture were exposed to cisplatin for 24 hrs and several endpoints of toxicity were measured
including production of ROS, cell death, apoptosis, and release of the immunoreactive calcitonin
gene-related peptide (iCGRP). Reducing expression of Ape1 in neuronal cultures using siRNA
enhances cisplatin-induced cell killing, apoptosis, ROS generation and the cisplatin-induced
reduction in iCGRP release. Overexpressing wild-type (WT)-Ape1 attenuates all the toxic effects of
cisplatin in cells containing normal endogenous levels of Ape1 and in cells with reduced Ape1 levels
following Ape1siRNA treatment. Overexpressing the redox deficient/repair competent C65-Ape1
provides partial rescue, while the repair deficient Ape1 (N226A+R177A) does not protect neurons
from cisplatin toxicity. We also observe an increase in phosphorylation of p53 following a decrease
in Ape1 levels in sensory neuronal cultures. These results strongly support the notion that Ape1 is a
potential translational target such that protecting Ape1 levels and particularly its DNA repair function
could reduce peripheral neuropathy in patients undergoing cisplatin treatment.
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Introduction
Cisplatin is one of the most commonly used cytotoxic agents in the treatment of a variety of
solid malignant tumors including testicular, bladder, lung, esophagus, stomach, ovarian cancers
as well as sarcomas and lymphomas (1). One of the major limitations of the use of cisplatin,
however, is peripheral neuropathy (2,3) which appears to be caused mainly by the action of
the drug on dorsal root ganglion (DRG) neurons (4). Cisplatin therapy and cytotoxicity has
been shown to involved the formation of intrastrand and interstrand adducts in DNA (5) and
this is thought to be one of the major mechanisms for cisplatin-induced damage in sensory
neurons (3,6) Indeed, mice deficient in nucleotide excision repair (NER), the pathway once
thought to be the major repair response to cisplatin, show an increase in symptoms of
neuropathy after cisplatin treatment compared to mice with NER intact (7). However, there is
growing evidence suggesting that cisplatin toxicity is closely associated with increased
generation of reactive oxygen species (ROS) (8–10).
Apurinic/apyrimidinic endonuclease/redox factor (Ape1/Ref-1; which will be called Ape1) is
a ubiquitous multifunctional protein involved in the DNA base excision repair (BER) pathway
of oxidative DNA damage that can occur from either endogenous or exogenous agents
generating ROS (11–13). In addition, Ape1 functions as a major reducing-oxidizing (redox)
factor augmenting the binding activity of a number of transcription factors to DNA including,
but not limited to NFkB, p53, AP-1, and CREB (13). In neurons, these transcription factors
play important roles in neuronal survival, stress response and various disorders (14–16).
Previous studies by our laboratory demonstrated that Ape1 protects sensory neuronal cells from
oxidative DNA damage, secondary to exposure to H2O2 (17). Other groups have demonstrated
that overexpression of Ape1 protected melanoma cells from cisplatin or H2O2 induced
apoptosis (18) and we have shown that Ape1 overexpression protected germ cell tumor cells
from radiation and bleomycin treatment (19). Thus, there is precedent in mitotic cancer cell
lines that Ape 1 plays a role in cisplatin induced cell death. The question remains, however,
whether Ape 1 could be neuroprotective against cisplatin-induced toxicity in postmitotic
sensory neurons and thus have the potential to reduce peripheral neuropathy. In this article, we
demonstrate that cisplatin produces significant amounts of ROS in sensory neuronal cultures
and that reducing Ape1 expression in these cultures results in an increase in cisplatin-induced
neurotoxicity and an increase in the activity of the p53 signaling pathway. Conversely
overexpressing wild type and redox deficient Ape 1 in neuronal cultures attenuates cisplatin-
induced toxicity while a repair deficient Ape1 does not. These findings have potential
translational applications such that modifying or protecting the function of Ape1 in neuronal
cells may have chemoprotective effects for patients undergoing chemotherapy with platinating
agents.
Materials and Methods
Cell culture
Adult dorsal root ganglion neuronal cell cultures were prepared as previously described (20,
21). Briefly, adult male (150–175g) Sprague-Dawley rats (Harlan, Indianapolis, IN) were
euthanized by CO2 asphyxiation. Dorsal root ganglia (DRG) were collected from the spinal
column, incubated in collagenase, and mechanically dissociated. For studies measuring cell
viability, ROS, apoptosis and signaling approximately 60,000 cells were plated into each well
of poly-D-lysine and laminin coated 6-well culture plates. For studies measuring CGRP release,
approximately 15,000 cells were plated in 12 well culture plates. Cells were maintained in F-12
media (Invitrogen, Carlsbad, CA) supplemented with 10% horse serum, 2mM glutamine,
100μg/ml normocin, 50μg/ml penicillin, 50μg/ml streptomycin, 50μM 5-fluoro-2′-
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deoxyuridine (Invitrogen), 150μM uridine, and 30ng/ml of NGF(Harlan Bioproducts for
Science, Inc. Indianapolis, IN) in 3% CO2 at 37°C.
Cell viability assays
To assay cell viability, trypan blue exclusion analysis was performed as previously described
(17). Cells were resuspended using a 0.05% trypsin EDTA solution. Equal volumes of the cell
suspension and 0.4% (w/v) trypan blue in phosphate-buffered saline (PBS) were mixed and
the cells scored under phase contrast microscope.
ROS Measurement
Sensory neuronal cell cultures were treated with cisplatin for 24 hrs. After washing with PBS,
the cells were incubated with 10μM carboxy-H2DCFDA (Invitrogen, Carlsbad, CA) in fresh
PBS for 60 min (22). Excessive probe was washed off with PBS, and cells incubated in PBS
for another 60 min at 37°C. The cells were harvested with trypsin and fluorescence of the
labeled cells was measured by using a Coulter EPICS XL flow cytometer (Coulter). An average
of 10,000 cells from each sample was counted.
Ape1siRNA transfection
To decrease Ape1 in sensory neuronal cell cultures, Ape1siRNA and SCsiApe1 (scrambled
control) were used as described previously (17,23). Briefly, on the fourth day in culture, the
growth media was replaced with 0.5 ml of Optimem I medium containing 10 μl of the
transfecting reagent Neuroporter in the absence or presence of the 21-mer oligonucleotide
double-stranded siRNA to Ape1 (Ape1siRNA) or scrambled Ape1siRNA (SCsiRNA). Fresh
medium (0.5 ml) without antibiotics was added after 24 hrs of incubation and after an additional
24 hrs, the medium was replaced with normal medium containing antibiotics and cell growth
maintained.
Adenoviral infection
Adult sensory neuronal cell cultures were grown for eight days and then infected with either
the wild-type Ad5 HA-Ape1 (WT-Ape1), the redox deficient/DNA repair competent Ad5 HA-
C65A (C65-Ape1), DNA repair deficient/redox competent Ad5 HA-N226A+R177A (N226
+R177-Ape1), or vector control Ad5 IRES2EGFP (Vector) adenovirus at 150 pfu/cell for 24
hrs by adding the virus directly to the growth medium as previously described (17). The N226A
+R177A Ape1 double mutant has been shown to decrease the ability of this mutant Ape1 to
bind to AP sites in DNA (24). The constructs used contained the human Ape1 sequence so that
the rat Ape1-siRNA oligonucleotides could not bind to it because of sequence differences
between human and rat. However, the codons are highly conserved as are their functions. The
Hemagglutinin epitope (HA) tag was added to the amino terminus of Ape in order to distinguish
exogenous transgene overexpression from endogenous Ape1 gene levels and has been routinely
used by us (17). After 24 hrs, the medium containing adenovirus was aspirated and replaced
with culture medium. Infection efficiencies of transduced cells were determined 24 hrs after
infection by fluorescence microscopy.
Cisplatin treatment
Adult sensory neuronal cultures were grown in culture for 11 days, with or without siRNA
transfection and with or without adenovirus infection (vector, WT-Ape1, 226+177-Ape1, C65-
Ape1), the cells were washed, treated with cisplatin at various concentrations and analyzed as
described in the results section. Cisplatin (Sigma-Aldrich, St. Louis, MO) was prepared fresh
for each experiment by dissolving in N,N-dimethylformamide (Sigma-Aldrich, St. Louis, MO)
with the final N,N-dimethylformamide concentration less than 0.005%.
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Western Blot Analysis
Cells in culture were harvested and lysed in an ice-cold RIPA lysis buffer (Santa Cruz
Biotechnology, Inc. Santa Cruz, CA). Protein concentration was quantified using the detergent-
compatible (25). Lowry-based protein assay (Bio-Rad Laboratories, Hercules, CA). Protein
(20–40μg) was electrophoresed in SDS gel-loading buffer on a 10% SDS-polyacrylamide gel.
After electrophoresis, the gel was transferred to a PVDF membrane. The membrane was
incubated with a primary antibody against Ape1 (17,26), phosphor-histone H2AX (Ser139)
(Upstate Cell Signaling Solutions, Charlottesville, VA), phosphor-p53 (Ser15) (Cell signaling
Technology, Beverly MA), p53, Gadd45a (C-4) (Santa Cruz Biotechnology Inc., Santa Cruz,
CA). Generally antibodies were used at dilutions of 1:1000 or 1:1500. After incubated with
HRP-conjugated secondary antibody (Santa Cruz Biotechnology Inc.), Antibody binding was
detected using chemiluminescence (Roche Diagnostics Corp., Indianapolis, IN), and equal
loading was confirmed by probing with β-actin monoclonal antibody (NeoMarkers, Inc.,
Fremont, CA).
Cell apoptosis Analysis
Apoptosis was quantitated using flow cytometry after cell treatment using Annexin V-APC
and 7-amino-actinomycin D (7-ADD) and the Annexin V-Apoptosis Detection kit (BD
Biosciences, San Diego, CA) according to the manufacturer’s instructions. Apoptotic cells
were defined as those positive for Annexin V with or without 7ADD staining.
Calcitonin gene-related peptide (CGRP)
Release studies were performed on the cells as previously described (17). Briefly, the neuronal
cultures were washed once with HEPES buffer consisting of (in mM) 25 HEPES, 135 NaCl,
3.5 KCl, 2.5 CaCl2, 1 MgCl2, 3.3 D-glucose, and 0.1% bovine serum albumin, pH 7.4 and
maintained at 37 C, then incubated for successive 10 min intervals with 0.4 ml of the same
buffer in the absence or presence of drugs. Basal or resting release was determined by exposing
the cells to HEPES buffer alone, whereas stimulated release was determined by exposing the
cultures to 30 nM capsaicin. Cells then were reexposed to HEPES buffer without drugs for one
or two 10 min incubations to reestablish resting release. During incubations, the cells were
maintained in at 37°C. After each incubation, the buffer was removed to measure the amount
of CGRP using radioimmunoassays (RIAs) as previously described (17). At the end of each
release experiment, the cells are scraped and sonicated in 0.4 M HCl and an aliquot taken to
measure total CGRP content in the cultures using radio immuno assay (RIA). Total content is
determined by adding the total amount released in all incubations to the amount remaining in
the cells. The release data is calculated as a % of the total peptide content in the cells. Because
CGRP was measured by RIA, results were expressed as CGRP-like immunoreactivity
(iCGRP).
Statistical Analysis
Data are expressed as the mean ± standard error, for at least three independent experiments
from separate harvests. Statistical analysis was performed using ANOVA. *p<0.05 vs. control
group.
Results
Effects of cisplatin on sensory neuronal cultures
Cisplatin-induced cytotoxicity—In the first series of experiments, we determined the
cytotoxic effect of cisplatin on sensory neuronal cultures by exposing cultures to various
concentrations of cisplatin for 24 hrs then measuring cell viability using the trypan blue
exclusion assay. As shown in figure 1A, exposing sensory neurons to cisplatin causes a
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concentration dependent decrease in cell survival. Twenty-five μM cisplatin for 24 hr had no
significant effect on cell viability, whereas with 400 μM cisplatin only 4 ± 0.01 % of the cells
survived. The calculated LD50 for cisplatin in these experiments was 80 μM.
Cisplatin-induced ROS generation—Although it is clear that cisplatin results in DNA
adducts in sensory neurons (6,7), recent evidence suggests that the drug also can produce ROS
in non-neuronal cells (27). To determine if cisplatin could produce ROS in sensory neurons,
cultures were exposed to increasing concentrations of cisplatin for 24 hours and ROS measured
using carboxy-H2DCFDA and FACS analysis as described in methods. In a manner analogous
to cell eviability studies, 25 μM cisplatin was not effective, i.e. it did not increase ROS, whereas
with concentrations of 50 μM, 100 μM and 200 μM cisplatin ROS was significantly higher
then untreated controls. As a positive control in these experiments, cultures were exposed to
100 μM Tert-Butyl hydroperoxide (TBHP) for 1 hour (28), but the increase in ROS was not
as high as that observed with higher concentrations of cisplatin. These data support our
contention that ROS and oxidative DNA damage are important components of cisplatin’s
deleterious effects on neuronal cells.
Cisplatin-induced increase in Ape1 expression—Several studies have demonstrated
that ROS enhanced Ape1 expression in gastric epithelial, ovary, macrophages and liver cells
(29,30). The question of whether chemotherapeutic agents, especially those typically classified
as DNA crosslinking agents alter Ape1 expression has not been addressed. Therefore, we
examined whether Ape1 expression in sensory neuronal cultures would be altered by exposing
cells to cisplatin. For these experiments, cultures were exposed to various concentrations of
cisplatin for 24 hrs and Ape1 protein expression analyzed using immunoblotting. As shown in
figure 1C, Ape1 protein levels were not significantly increased when cells were exposed to
6.25 μM or 12.5 μM cisplatin, but were significantly higher than controls at 25 μM and higher.
Increased Ape1 expression levels were also observed in cells 48 hrs after treatment with
cisplatin (data not shown).
Reduced expression of Ape1 enhances cisplatin-induced cytotoxicity and ROS production
in sensory neuronal cultures
Because cisplatin increased ROS and Ape1 expression in sensory neurons, we examined
whether reducing Ape1 expression in sensory neuronal cultures would augment cisplatin-
induced cell death. Exposing neuronal cultures to Ape1siRNA significantly reduced the
expression of Ape1 compared to levels in cultures exposed to SCsiRNA (see figure 2A for a
representative western blot). This reduction of Ape1 resulted in a statistically significant
increase in cisplatin-induced cytotoxicity compared to the SCsiRNA controls (figure 2B). The
increase in cell killing was approximately 20% greater when Ape1 levels were decreased
compared to cells treated with SCsiRNA.. This result demonstrates that reduction of Ape1
expression in sensory neuronal cells significantly increases cisplatin-induced cytotoxicity.
We also examined ROS production in cultures exposed to SCsiRNA or Ape1SiRNA. In these
experiments Ape1siRNA treatment reduced Ape1 expression by 70% compared to cultures
exposed to SCsiRNA (data not shown). This decrease in Ape1 expression resulted in a
significant increase in the ROS generated by a 24 hr exposure to 50 μM or 100 μM cisplatin,
to 10 and 16 percent, respectively (figure 2C) compared to SCsiRNA treated cultures.
Cisplatin treatment (50 μM) enhanced the level of Ape1 expression in cultures from 4 to 48
hrs after a 24 hr exposure in cultures treated with SCsiRNA (figure 2D) in a manner a
comparable to that observed in previous experiments (figure 1A), but this did not occur in
cultures exposed to Ape1siRNA.
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Ape1 overexpression in sensory neuronal cells in cultures protects against cisplatin-
induced cytotoxicity
Because reducing Ape1 expression in sensory neuronal cultures augments cisplatin-induced
toxicity, we determined whether overexpressing Ape1 could be neuroprotective. WT-Ape1,
C65-Ape1, or vector control adenoviral constructs containing an IRES site and an enhanced
green fluorescent protein (EGFP) construct were used to infect sensory neuronal cell cultures
pretreated with either SCsiRNA or Ape1siRNA. The cells were transfected with Ape1siRNA
on days 4–6 in culture, infected with WT-Ape1 or the C65-Ape1 adenovirus on day 8, treated
with cisplatin (50uM or 100uM) on day 11 and cell viability assessed using trypan blue after
24 hrs of exposure to cisplatin. In all experiments we confirmed expression of the transgene
proteins by performing western blots on cultures at the end of each experiment and using HA-
antibody. As shown in representative Western blot in figure 3A, after transfecting with
Ape1siRNA the expression of Ape1 was lower than Ape1 levels in cultures treated with
SCsiRNA. After infection with viral vectors, however, the Ape1 expression was higher (figure
3A). When cells treated with SCsiRNA and the viral vector control were exposed to cisplatin
there was a significant reduction in cell survival (figure 3B, left panel). Cell viability was
reduced from 95% in cells not exposed to cisplatin to 65 +/− 5% and 51 +/− 3% after 50 μM
and 100 μM cisplatin, respectively. With a reduction in Ape1 expression, vector treated cells
showed an augmentation of cisplatin-induced neurotoxicity (figure 3B, right panel) and these
results are analogous to the finding presented above. Overexpressing either WT-Ape1 or C65-
Ape1 significantly rescued cells from killing by cisplatin. This occurred independent of
whether the cells had reduced Ape1 levels secondary to siRNA treatment. However, the
protective ability of C65-Ape1 was not equivalent to that of the WT-Ape1. For example, in
cells treated with Ape1siRNA, overexpressing WTApe1 increased cells viability after 100
μM cisplatin to 50 +/− 6%, whereas the C65-Ape only increased viability to 32 +/− 3%.
Overexpression of Ape1 reduces cisplatin-induced an apoptosis in sensory neuronal
cultures
Apoptosis has been observed in sensory neurons following cisplatin treatment in vitro and in
vivo (31,32). To ascertain whether Ape1 affects cisplatin-induced apoptosis in sensory neuronal
cultures, we performed apoptosis assays using Annexin-V/PI flow cytometry analysis. The
time line for these experiments is analogous to the previous studies but after 24 hr exposure to
100 μM cisplatin GFP positive cells were gated and cells undergoing apoptosis were detected
by Annexin and 7ADD staining. As shown in the representative experiment in figure 4A and
the summary data from 6 experiments in figure 4B, 22 ± 4% of cells from cultures exposed to
SCsiRNA, viral vector and cisplatin were apoptotic. In cells treated with Ape1siRNA, vector
and cisplatin 46 ± 6 were apoptotic. Overexpressing C65-Ape1 did not significantly rescue the
cells from cisplatin-induced apoptosis, whereas over expressing WT-Ape significantly
decreased the number of apoptotic cells independent of whether the cells were exposed to
SCsiRNA or Ape1siRNA (figure 4). Even though we do not see a significant difference
between the overexpression of C65-Ape1 compared to the vector control, there does appear to
be a trend in the direction of the C65-Ape1 providing protection.
Effect of Ape1 on cisplatin- altered evoked release of iCGRP from sensory neurons
We examined the effects of cisplatin in the absence or presence of Ape1 manipulations on the
release of iCGRP from sensory neurons in culture as an integrated functional output from these
cells. For these studies, sensory neuronal cultures in the absence or presence of Ape1
manipulations were exposed to various concentrations of cisplatin for 24 hours, then release
studies were performed as outlined in the methods. For internal consistency the release studies
were always performed on cells grown in culture for 12 days. Exposing sensory neurons in
culture to various concentrations of cisplatin results in a concentration dependent decrease in
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the capsaicin-evoked release of iCGRP (figure 5A). 3 μM cisplatin did not alter release
compared to untreated cells (11.3 ± 0.3 % of total iCGRP content for controls versus 12.9 ±
0.9 % for treated cells). In contrast both 10 μM and 30 μM cisplatin reduced the capsaicin-
evoked release to 6.3 ± 0.2 and 3.5 ± 0.1 % of total content, respectively. Cisplatin treatment
had no significant effect on basal release of iCGRP from sensory neurons. Basal release in
untreated cells was 7.7 ± 2.0 fmol/well of cells/10 min and was 7.0 ± 0.1, 7.4 ± 2.0, and 7.1 ±
0.2 fmol/well/10 min after 3, 10, or 30 μM cisplatin, respectively (data not shown). For the
remaining studies we used a concentration of 10 μM cisplatin since it produces a significant
decrease in iCGRP release, but does not cause cell death in the cultures (see figure 1).
When neuronal cultures were exposed to SCsiRNA or Ape1siRNA in the absence of cisplatin
treatment, there was no significant effect on capsaicin-evoked release compared to untreated
controls (figure 5B). When cells were exposed to SCsiRNA, which did not reduce levels of
Ape1, 10 μM cisplatin for 24 hrs significantly reduced cisplatin-evoked release to 7.0 ± 0.2 %
of total iCGRP content, which is to the values observed in control cells treated with 10 μM
cisplatin (figure 5A). Reducing Ape1 expression using siRNA, however, significantly
augmented the ability of cisplatin to reduce peptide release to 4.8 ± 0.3 % of total content
(Figure 5B).
As in previous studies, we next determined if overexpression of Ape1 or Ape1 mutants could
reverse the effects of cisplatin on iCGRP release. As in previous experiments, cultures were
first treated with siRNAs, infected with viral vectors, exposed to 10 μM cisplatin for 24 hrs,
than basal and capsaicin-evoked iCGRP release measures. When cells treated with SCsiRNA
or Ape1siRNA were infected with the vector control, cisplatin treatment resulted in a
significant decrease in capsaicin-evoked release of iCGRP in a manner analogous to untreated
cells (figure 5C). In contrast overexpression of WT-Ape1 or C65-Ape1 significantly attenuated
the effects of cisplatin (figure 5C). The addition of siRNA and viral vectors in cells not exposed
to cisplatin did not alter basal or capsaicin evoked release of iCGRP (data not shown). In
addition no treatment regime significantly affected basal release.
These data suggest that the repair component of Ape1 is involved in reversing the effects of
cisplatin on peptide release from sensory neurons. To further substantiate this notion,
experiments were performed using overexpression of another mutant Ape1, N226A+R177A-
Ape1 (24). This mutant has the redox component of WT-Ape1, but no repair function (24).
When this mutant was overexpressed in sensory neuronal cultures it had no effect on the ability
of cisplatin to reduce capsaicin-evoked release of iCGRP (figure 5C).
Effect of Ape1 on DNA damage and expression of transcription factors in sensory neuronal
cultures
Although the data above indicate that Ape1 is neuroprotective against cisplatin induced
neurotoxicity, the question remains what is the mechanism of this protection. Thus, in order
to determine if exposing sensory neurons to cisplatin would alter the phosphorylation of histone
H2A.X as an indicator of double strand breaks (26) and transcription factors that are
downstream of Ape1 that are under redox control by Ape1 such as the transcription factor, p53
(33). Sensory neuronal cultures were treated with either SCsiRNA orApe1siRNA, followed
by 50 uM cisplatin and the cells harvested after 8, 24 and 48 hr exposure. When cells treated
with SCsiRNA were exposed to cisplatin, there was a small increase in H2AX phosphorylation
and phosphorylation of p53 at the serine 15 position over time (figure 6A and 6B). Figure 6A
shows a representative Western blot, whereas figure 6 B shows summary results from three
experiments. These increases were not significantly different from cultures not exposed to
cisplatin (time zero). There also was no significant change in Gadd45a expression as measured
by western blotting. In contrast, in cells treated with Ape1siRNA phosphorylation of H2AX
was significantly higher after 48 hrs of cisplatin exposure (figure 6A and 6B). Phosphorylation
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of p53 was also significantly higher in cultures with reduced Ape1 expression after 24 and 48
hrs of cisplatin treatment. Gadd45a protein was also greatly augmented at 24 hours in the
Ape1siRNA knockdown sensory neuronal cells compared with SCsiRNA controls. This time
course indicates an increase in the p53 response pathway leading to an increase in Gadd45a
following p53 activation 24–48 hrs after cisplatin treatment and with the reduction of Ape1 in
cells.
Discussion
This report is the first data demonstrating a role of a BER protein, Ape1, in sensory neuronal
survival and function following cisplatin treatment. Furthermore, we demonstrate that it is
largely Ape1’s repair function that is involved in the response of sensory neuronal cells to
cisplatin stress and that cisplatin causes an alteration of the p53 signaling pathway. We chose
to examine the effects of cisplatin on sensory neurons since the neuropathy caused by this
anticancer drug is largely sensory and often involves paresthesia and/or overt pain (34).
Furthermore, platinum binding to DNA in sensory neurons is high (3,6) and exposing isolated
sensory neurons to cisplatin causes apoptosis (32). In this report, we observed a concentration-
dependent increase in sensory neuronal cell killing and apoptosis after cisplatin, confirming
the previous studies. Of interest, however is the fact that a 10 μM over 24 hours significantly
reduced the release of iCGRP from sensory neurons. We did not observe any significant change
in the content of iCGRP in the cultures after exposure to cisplatin (data not shown), thus the
cisplatin-induced alterations in release were not secondary to cell death or loss of transcription.
Our observation of a decrease in evoked release of iCGRP after cisplatin exposure, are similar
to in situ studies demonstrating that treating rats with 1.5 mg/kg cisplatin once per day for 5
days results in a decrease in stimulated-release of the neuropeptides substance P, somatostatin
and CGRP from the lower trachea and main bronchi (35). The cisplatin-induced decrease in
CGRP release from sensory neurons suggests a loss of function of these neurons that could
have important consequences. The release of CGRP from peripheral terminals of small
diameter sensory neurons is associated with local vasodilation that contributes to neurogenic
inflammation (36). Indeed, CGRP is a potent vasodilator and a decrease in its release could
negatively impact local blood flow and contribute to symptoms of peripheral neuropathy. At
central terminals of sensory neurons, CGRP may contribute to thermal sensation as well as
nociception. Thus a decrease in its release in response to stimuli could result in reduced sensory
input. The potential impact of a decrease in CGRP release on nociception still needs to be
determined. Cisplatin has been shown to induce ROS generation in a selected number of cell
systems (10,37) and the increase in ROS could damage lipids, proteins, and nuclear and
mitochondrial DNA, leading to cell death (38). Oxidative damage has been suggested as the
main cause of cisplatin-induced renal cell death and several antioxidants and radical scavengers
alleviate cisplatin-induced nephrotoxicity in vitro and in vivo (39,40). Recently, it was
demonstrated that inhibiting mitochondrial respiration results in an enhancement of cisplatin
toxicity to leukemic cells (10) and an imbalancing of the BER pathway in mitochondria using
the OGG1 protein leads to enhanced cisplatin toxicity (10). In line with these studies, our results
demonstrate a significant increase in intracellular ROS concentration in sensory neuronal cells
follow cisplatin exposure (figures 1 and 2). The basal increase in ROS production in sensory
neuronal cells parallels a significant increase in Ape1 expression; the first time an induction
of Ape1 has been seen following cisplatin treatment. Furthermore, reducing Ape1 expression
augments cisplatin-induced ROS production. This correlates with previous studies in tumor
cell lines that demonstrated cisplatin apoptosis is mediated by ROS production and Ape1
overexpression can suppress this ROS production (18,41,42).
The question remains as to the mechanisms by which cisplatin induced toxicity in sensory
neurons. Previous work shows a correlation between the platinum binding to DNA and the
toxicity in sensory neurons (3,6). This would imply that the nucleotide excision repair pathway
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is important in regulating cisplatin-induced toxicity and in mice deficient in NER function;
there is an increase in accumulation of unrepaired cross-links and in neurotoxicity (7). Our
current findings, however, demonstrate that Ape1 plays a role in reducing cisplatin-induced
neurotoxicity. We demonstrate that reducing Ape1 by siRNA increased cisplatin-induced ROS
production (figure 2) and also increased cell killing and apoptosis (figures 3 and 4) and deceased
iCGRP release (figure 5). Moreover, over expression of Ape1 in DRG cells or siRNA
knockdown DRG cells resulted in increased protection from cisplatin. Our current results
further suggest that the repair component of Ape1 plays a major role in its ability to protect
against cisplatin-induced toxicity. In most studies both wild-type Ape1 and the C65-Ape1
repair competent/redox deficient protein protected the cells, although overexpression of the
C-65 mutant was effective at an intermediate level. In contrast, the N226A+R177A-Ape1
which has the redox component of WT-Ape1, but no repair function (24), was not effective in
blocking the ability of cisplatin to decrease iCGRP release.
In order to begin to determine the mechanistic and signaling pathways that may be involved
in the response of DRG cells to cisplatin induced stress and the role of Ape1 in this process
we studied the role of the p53 stress response pathway. We chose this pathway to begin our
analyses given the previously demonstrated interactions between Ape1 and p53 in tumor and
normal, dividing cells (33,43) and since the p53 tumor suppressor protein plays a major role
in cellular response to DNA damage and other genomic aberrations, particularly in mitotically
growing cells. p53 is a nuclear phosphoprotein and phosphorylation of Ser15, a key
phosphorylation target during the p53 activation process, has been shown as being critical for
p53-dependent transactivation(44). DNA damage induces phosphorylation of p53 at Ser15 and
leads to reduced interaction between p53 and its negative regulator, oncoprotein MDM2 (45,
46). To begin to examine this pathway, we performed studies using western blot analysis and
found that altering Ape1 levels leads to alterations in the amount phosphorylated-p53 and an
increase in Gadd45a protein levels (figure 6). Our results indicate an induction of p53
phosphorylation at Ser15 following the alteration of Ape1 levels and cisplatin treatment which
is the first time a relationship between Ape1 protein levels and p53 phosphorylation has been
observed. This change in p53 phosphorylation was correlated with an induction of Gadd45a
and implicates this pathway as the primary signaling pathway involving Ape1, cisplatin and
ROS in DRG cells. Gadd45a which is involved in the DNA repair, maintenance of genomic
stability, cell cycle control and apoptosis and its induction is primarily p53-dependent (47).
The p53-GADD45a pathway is also intimately linked to the repair of DNA damage related to
cross-linking agents or those that are normally repaired by the NER pathway (33,48).
Therefore, our findings reported here are consistent with alterations in Ape1 levels and
functions impinging on DRG survival and function by altering both BER and NER pathways.
While we present a number of novel findings in this report; induction of Ape1 by cisplatin,
knocking down Ape1 levels leading to increased ROS in post-mitotic cells, role of Ape1 redox
and repair functions in cisplatin survival and function of sensory neurons and the perturbation
of the p53-Gadd45a signaling pathway by Ape1, we have not completely delineated all the
mechanisms that may be acting with Ape1 perturbation in the DRG neuron. One of the areas
that will require additional study involves the role of the mitochondria in these cells and in the
DRG response to chemotherapeutic agents. For example, in a recent report, apoptosis induced
by cisplatin was shown to require the production of ROS, but was independent of damage to
nuclear DNA (49). Additionally, mtDNA has been shown to be naturally more sensitive to
oxidative damage than nuclear DNA (50). Therefore, studying the effects of cisplatin on the
mitochondrial genome and Ape1’s role in the repair of mtDNA damage following cisplatin
treatment warrants further investigation. It may turn out that the main response of DRG neurons
to cisplatin treatment is mediated through mitochondria ROS production such that altering
Ape1 leads to a suboptimal response of the mitochondria and a chain of events resulting in
DRG dysfunction or death.
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Figure 1. Effect of cisplatin treatments on sensory neuronal cells
A. Sensory neuronal cell cultures were incubated with different concentrations of cisplatin for
24 hrs. Cytotoxicity was determined using the trypan blue exclusion assay as described. Each
point represents the mean ± SE for three independent harvests of cells. Asterisks indicates a
statistically significant (*p<0.05) difference from control.
B. ROS generation in sensory neuronal cell cultures following cisplatin treatment. After
incubation with cisplatin for 24 hrs, sensory neuronal cell cultures were loaded with 10 μM
carboxy-H2DCFDA and incubated for 1 hour. Carboxy-H2DCFDA is an indicator for reactive
oxygen species (ROS) and only fluoresces when hydrolyzed by esterases and oxidation occurs
within the reaction system. The top portion of the figure shows the fluorescence of the oxidized
form of carboxy-H2DCFDA as analyzed in a representative flow cytometry experiment. As a
positive control for oxidative stress, cells were treated for 1 hr with 100 μM TBHP. The panel
at the bottom represents the summary of three experiments expressed as the amount of change
in fluorescent cells following cisplatin treatment. Each point represents the mean ± SE for three
independent harvests of cells. Statistically different points from controls are indicated with an
asterisk (*p<0.05).
C. Ape1 protein expression levels following cisplatin treatment. The panel on the top shows a
representative Western blot of the expression of Ape1 after sensory neuronal cell cultures were
incubated with different cisplatin concentrations for 24 hrs. The panel at the bottom represents
the summary of Ape1 expression following cisplatin treatment normalized to the amount of
actin detected by densitometry. Each point represents the mean ± SE for three independent
harvests of cells. Statistically different points from controls are indicated with an asterisk
(*p<0.05).
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Figure 2. Effect of Ape1 siRNA knockdown on sensory neuronal cells following cisplatin treatment
A. Sensory neuronal cells were incubated with 100 nM Ape1siRNA on day four in culture and
the Ape1siRNAs were removed on day six. Ape1 expression was analyzed on day eleven by
western blot. SCsiRNA (100 nM) was used as negative control.
B. Ape1siRNA knockdown and SCsiRNA transfected sensory neuronal cells were incubated
with cisplatin (0, 50, 100μM) for 24 hrs. The ordinate represents the percent of cell survival
measured by trypan blue exclusion. Each point represents the mean ± SE for three independent
harvests of cells. Statistically different points from controls are indicated with an asterisk
(*p<0.05).
C. ROS generation. The fluorescence of the oxidized form of carboxy-H2DCFDA was
analyzed by flow cytometry in SCsiRNA and Ape1siRNA knockdown cells. These data are
representative of four individual experiments. Statistically different points from controls are
indicated with an asterisk (*p<0.05).
D. Ape1 protein expression levels in SCsiRNA and Ape1siRNA knockdown DRG cells
following cisplatin 50μM treatment at indicated timepoints (left) as analyzed by Western blot.
The summary of Ape1 expression was normalized to the amount of actin detected by
densitometry (right). Each point represents the mean ± SE for three independent harvests of
cells. Statistically different points from controls are indicated with an asterisk (*p<0.05).
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Figure 3. Effect of Ape1 overexpression on sensory neuronal cell viability after cisplatin treatment
A. Sensory neuronal cells were incubated with 100 nM Ape1siRNA on day four in culture and
the Ape1siRNAs were removed on day six. The cells were then infected with one of three
adenoviral constructs; vector control, WT-Ape1or C65-Ape1 on day eight for 24 hrs. The level
of adenovirus infection was measured on day eleven by fluorescence microscope. Ape1
expression was analyzed on day eleven by western blot.
B. Survival of sensory neuronal cells following cisplatin treatment with or without Ape1
knockdown and the addition of transgene Ape1 constructs. The ordinate represents percent of
cells surviving at 24 hrs after various doses of cisplatin treatment as measured by trypan blue
exclusion in DRG cells, without (left) or with (right) Ape1 knockdown. Each point represents
the mean ± SE for three independent harvests of cells. Statistically different points from
controls are indicated with an asterisk (*p<0.05).
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Figure 4. Effect of Ape1 levels on the apoptosis levels of sensory neuronal cells following cisplatin
treatment
A. Sensory neuronal cell cultures were incubated with Ape1siRNA or SCsiRNA control oligos
and were then infected with either WT-Ape1 or C65-Ape1. The cells were then treated with
cisplatin (100uM) for 24hrs. The level of cells undergoing apoptosis were detected by Annexin-
V and 7ADD staining and FACS analysis as discussed in materials and methods.
B. Quantification of the data presented in A. The percentage of cells undergoing apoptosis
(c, lower right quadrant) plus late apoptosis (b, upper right quadrant) are shown. Statistically
different points from controls are indicated with an asterisk (*p<0.05).
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Figure 5. Effect of altered Ape1 levels on cisplatin-induced iCGRP release from sensory neuronal
cells
A. Sensory neuronal cells were treated for 24 hrs with increasing amounts of cisplatin. There
was a decrease in the amount of iCGRP released in the capsaicin-evoked release of iCGRP.
Each column represents the mean +/- SE of the percent of total content of iCGRP after exposure
to 30 nM capsaicin for nine wells of neurons.
B. Sensory neuronal cells were treated with cisplatin, Ape1-siRNA or SC-siRNA and/or virus
as indicated. Compared to untreated controls, SCsiRNA and Ape1siRNA treated cells had a
statistically significant (*p < 0.05) decrease in release after exposed to cisplatin.
C. Sensory neuronal cells were treated with cisplatin at 10 uM and either SCsiRNA or Ape1-
siRNA and then either adenoviral vector control or adenovirus with either WT-Ape1, C65-
Ape1 or N226A+R177A Ape1. There was a significantly significant increase in the release in
the C65A-Ape1 and the WT-Ape1 transgenes compared to the vector or the N226A+R177A-
Ape1 (p < 0.05).
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Figure 6. Effect of altering Ape1 levels on the p53 signaling and dsb pathway following cisplatin
treatment of sensory neuronal cells
A. A representative western blot analysis of the protein levels of p53 and Gadd45a and the
phosphorylation of p53ser15 and phosphorylation levels of H2AX. Sensory neuronal cell
cultures were incubated with Ape1siRNA or SCsiRNA control oligos and were then treated
with 50 μM cisplatin for 48 hrs.
B. The protein levels of three independent experiments following normalization to actin. Each
point represents the mean ± SE for at least three independent harvests of cells. Differences
were considered significant at *p<0.05.
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